Biologics in juvenile idiopathic arthritis: a narrative review

Conclusions: Research in pediatric rheumatology has resulted in dramatic advances in diseases management. Biologic treatments have improved physical and functional outcomes and quality of life of patients with rheumatic disease.What is Known:•NSAID, intra-articular injection of corticoids, and methotrexate are the mainstay in treatment of JIA.•In aggressive JIA, these treatments may be not sufficient to reach disease remission and to prevent long term disability.What is New:•In recent years, management of JIA has significantly improved with the development of biologic therapies that allowed children with arthritis to reach a normal growth and to achieve a good long-term functional outcome.
Source: European Journal of Pediatrics - Category: Pediatrics Source Type: research